Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial

INTRODUCTION: The effectiveness of umifenovir against COVID-19 is controversial; therefore, clinical trials are crucial to evaluate its efficacy. METHODS: The study was conducted as a single-center, randomized, open-label clinical trial. Eligible moderate-severe hospitalized patients with confirmed...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int Immunopharmacol
Main Authors: Alavi Darazam, Ilad, Shokouhi, Shervin, Mardani, Masoud, Pourhoseingholi, Mohamad Amin, Rabiei, Mohammad Mahdi, Hatami, Firouze, Shabani, Minoosh, Moradi, Omid, Gharehbagh, Farid Javandoust, Irvani, Seyed Sina Naghibi, Amirdosara, Mahdi, Hajiesmaeili, Mohammadreza, Rezaei, Omidvar, Khoshkar, Ali, Lotfollahi, Legha, Gachkar, Latif, Dehbsneh, Hadiseh Shabanpour, Khalili, Negar, Soleymaninia, Azam, Kusha, Akram Hoseyni, Shoushtari, Maryam Taleb, Torabinavid, Parham
Format: Artigo
Jezik:Inglês
Izdano: Elsevier B.V. 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270750/
https://ncbi.nlm.nih.gov/pubmed/34273635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2021.107969
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki